Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HERG CRISPR/Cas9 KO Plasmid (h): sc-401143
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HERG CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HERG genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HERG Antibody (F-12): sc-377388
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HERG CRISPR/Cas9 KO Plasmid (h) | sc-401143 | 20 µg | $397.00 |
Overview
KCNH2 encodes the human HERG voltage-gated potassium channel (Kv11.1), a key mediator of the rapid delayed rectifier current (IKr) that shapes phase 3 repolarization of the cardiac action potential. HERG activity integrates with broader ion channel networks and membrane excitability programs to control action potential duration, refractoriness, and rhythmicity. Disrupted KCNH2 function is strongly associated with inherited and acquired arrhythmia phenotypes, including long QT syndrome, and is a central node in electrophysiology and safety pharmacology research. Beyond cardiomyocytes, KCNH2 expression has been examined in excitable and non-excitable contexts where potassium conductance influences proliferation and cellular signaling states.
HERG CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KCNH2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KCNH2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KCNH2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HERG protein expression.
This CRISPR knockout system enables efficient generation of KCNH2-deficient cell models for investigation of HERG signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KCNH2 exon(s) critical for HERG function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KCNH2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HERG CRISPR/Cas9 KO Plasmid (h) and HERG CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KCNH2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HERG HDR Plasmid (h) and HERG HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KCNH2 homology arms to support homology-directed repair at defined KCNH2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.